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ABSTRACT 
CHARACTERIZ!<TION OF DANAZOL 
BINDING OF SPECIFIC 
CYTOSOL RECEPTORS 
IN VITRO 
Gail Wright Russell, M. S. 
Morehead State University, 1982 
The binding of danazol to specific cytosol receptors 
in• vitro was performed on uterine, mammary, adrenal, 
pituitary and hypothalamic tissue, using the hydroxyl-
apatite assay. This study was designed to determine the 
specificity of danazol binding to cytosol receptors, 
evaluate danazol's dose responsiveness and determine the 
ability of dahazol to translocate specific cytosol 
receptors into the nucleus. Results were obtained by 
using radioactively tagged estradiol, dihydrotestosterone, 
progesterone and corticosterone. 
Danazol was shown to bind and translocate each 
steroid receptor, though not significantly, while showing 
the greatest success with the androgen receptor in all 
tissues. The dose responsiveness of danazol was effec-
tively demonstrated by its increased competition at 
pharmacological concentrations. Furthermore., the 
results indicated that danazol was most effective in 
translocating the androgen receptor in mammary tissue. 
iii 
Accepted by: 
, Chairman 
tkwO/Lld~) 
Dr. Howard L. Setser 
iv 
ACKNOWLEDGEMENTS 
I would like to thank the members of my committee, 
Dr. David Brumagen and Dr. Howard Setser, for their time 
and criticism of this work. To Dr. David Magrane, 
chairman of my committee, I express the most heartfelt 
thanks. It was through his guidance and support that I 
felt confident enough to seek a masters degree in biology. 
The encouragement given and many hours devoted towards 
the completion of this paper is sincerely appreciated. 
Grateful appreciation is expressed to John Razor for 
allowing me the use of the scintillation counter at Maxey 
Flats and to Mary Kornman for performing the counts. I 
would also like to extend a special gratitude to Debbie 
Spencer for her technical assistance. 
Particular appreciation goes to Bea Falls, for the 
time given and patience shown while typing this paper and 
to my husband, Don; who has been most understanding and 
cooperative throughout the research and writing of this 
thesis. 
V 
TABLE OF CONTENTS 
I. Introduction . . . . . 
II. Materials and Methods. 
Page 
l 
12 
Animal Care. . . 12 
Tissue Preparation. 12 
Isolation of Cytosol and ~uclear 
Receptors . . • . . . . . . . -13 
Receptor Incubations. . . . • . . 14 
Binding Competition Experiments. 15 
Dose Response Experiments. • . . 15 
Nuclear Translocation Experiments 16 
Hydroxylapatite Assay 17 
Protein Assay. . • . 17 
Statistical Analysis. 18 
I'.II. Results .. 
IV. Discussion 
V. Literature Cited 
vi 
19 
30 
34 
Figure 
1. 
2. 
3. 
4. 
5. 
6. 
7. 
8. 
LIST OF FIGURES 
Mechanism of action of steroid 
hormones. . . . . . . . . . . . 
Induction of progesterone receptor 
by estradiol (McGuire, et al, 1979) 
Summary of distribution of ER and 
PgR in human breast tumors (McGuire, 
1977) . • • • . . . • 
Structure of danazol. 
Titration curves of specific binding 
of 3H-estradiol to cytosol receptors. 
Danazol competition for steroid 
receptors in mammary tissue .. 
Danazol competition for steroid 
receptors in uterine tissue •. 
Danazol competition for steroid 
receptors in pooled adrenal tissue. 
vii 
Page 
2 
4 
7 
8 
21 
22 
23 
24 
Table 
1. 
2. 
LIST OF TABLES 
Danazol competition for steroid 
receptors in hypothalamic tissue. 
Comparison of steroid binding 
competition by danazol at 10-9 M. 
3. In vitro translocation of uterine 
androgen receptor in pre-puberal 
4. 
rats. . . . . . . . . . . . . . . 
In vitro translocation of uterine 
steroid receptors in adult rate. 
viii 
Page 
20 
26 
27 
28 
INTRODUCTION 
The intrace,llular mechanisms underlying steroid 
regulation of target cells are not fully understood. 
However, important events in the regulation appear to be 
steroid entry into cells of the specific target tissue, 
interaction of the steroid with its specific cytosol 
receptor, and translocation of the steroid-receptor 
complex to the cell nucleus. Presumably this leads to 
initiate messenger RNA (ribonucleic acid) and protein 
synthesis (Figure 1). 
An important factor in establishing. the current 
understanding of the mechanism of steroid hormone action 
was the synthesis of isotopically labeled compounds, they 
provided the first molecular probes to discern the 
sequence of events that occur following the interaction 
of a steroid hormone with a target cell (Jensen and 
Jacobson,1962). The use of tritium ( 3H) labeled compounds 
has also become very prominent in estrogen receptor 
studies involving breast cancer. 
An increased incidence of new cases of breast cancer 
annually in the United States and numbers of deaths due 
to the disease has created a greater interest towards 
studies evaluating estrogen receptors and their role in 
treatment of malignant and benign tumors. Witliff (1977) 
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Figure 1. Mechanism of action of steroid hormones. 
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suggests that a tissue demonstrating estrogen receptors 
should be classified as an estrogen target and should 
require hormone for maintenance and growth. Removal of 
estrogen should result in regression or involution of the 
tissue. In contrast, tissue lacking estrogen receptors 
should not be effected by removal of endogenous hormone. 
The first evidence of a relationship between the associ-
ation of 3H hormones with a breast tumor and the clinical 
response of the patient to ablative hormone therapy was 
shown by Folca and associates in 1961 (Folca, Glascock, 
and Irvine, 1961). Other research also substantiates 
Witliff's proposal showing that 25-40% of patients with 
inoperable breast cancer have neoplasms that regress 
after either the administration or pharmacological con-
centrations of hormones, such as androgens and estrogens, 
or removal of endogenous hormones, such as by ovariectomy 
or adrenalectomy (_Kennedy, 1974). These findings suggest 
that some malignant breast tumors may be hormone 
dependent. 
The concept underlying endocrine therapy is that 
certain tumor cells have retained their ability to respond 
to the same hormonal stimuli as their normal progenitor 
cells (Witliff, 1977). It is therefore suggested that 
the presence of specific estrogen receptors in human 
breast carcinomas may be predictive of a patient's 
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response to endocrine therapy (Garola and McGuire, 1978, 
Witliff, 1977, and McGuire, 1975). 
Other steroid receptors are also present in human 
breast cancer cells and may provide additional information. 
For example, Horwitz et al (1975) predict that the pre-
sence of progesterone receptors in a tissue should be an 
even more sensitive indicator of potential ·responsiveness 
to endocrine therapy than the estrogen receptor. The 
basis for such a prediction is the underlying concept 
that progesterone effects require estrogen priming, 
thereby inducing the synthesis of the progesterone· 
receptor (Figure 2). 
r 
llJRNA 
Figure 2. Induction of progesterone receptor by 
estradiol (McGuire et al, 1978). 
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Thus, the presence of progesterone receptors in a 
tumor would indicate that the entire sequence, involving 
estrogen binding to a cytoplasmic receptor, movement of 
the receptor complex into the nucleus, and stimulation 
of a specific end product, can be achieved in a tumor 
cell. This would rule out the existence of a defect be-
yond the binding step (McGuire -et al, 1978). Therefore, 
the presence of progesterone receptors in cancerous 
tissue will show that the tumor remains under at least 
partial endocrine control and may be classified as endo-
crine responsive. In support of the prediction, research 
showed 56% of tumors with estrogen receptors also had 
progesterone receptors, and tumors without estrogen 
receptors also lacked progesterone receptors lHorwitz 
et al, 1975). Preliminary data show only those breast 
tumors with progesterone receptors regressed after 
endocrine therapy. Continuation of estrogen and pro~ 
gesterone receptor studies together with research directed 
toward the evaluation of other steroid receptors present 
in human breast carcinomas, such as androgens and gluco-
corticoids may give hope of treatment for those patients 
with estrogen-receptor positive but unresponsive tumors. 
In research by McGuire (19.771, it was shown in 
randomly tested human breast tumors that 75% were 
estrogen-receptor positive (ER+), with 74% of the ER+ 
6 
tumors also having progesterone receptors (PgR) and only 
9% of the ER tumors having PgR. Where primary versus 
metastatic tumors were examined, 77% of the primary 
tumors were ER+ with 77% of them containing PgR and 66% 
of the metastatic tumors with ER+ with only 59% of them 
having PgR (Figure 3). 
Danazol is an isoxazole derivative of the synthetic 
steroid 17 a-ethinyltestosterone (Figure 4). It acts 
through the suppression of gonadal function (Chamness 
et al, 1980), and may possibly be used in future treat-
ment of hormonally dependent cancers, particularly those 
of the breast and endometrium (Jenkin, 1980). Support 
for the use of danazol was strengthened by the reported 
increased incidence of breast cancer in patients with a 
history of benign breast diseases (Humphrey and Swerdlow, 
1962, Davis• et al, 1964, Veronesi and Pizzocaro, 1968, and 
Dmowski and Cohen, 1978), and the fact that danazol has 
been shown to cause relief o_f various disorders of the 
breast (Greenblatt· et al_, 1971, Lauersen and Wilson, 
1976, Asch and Greenblatt, 1977, and Blackmore, 1977a). 
The attempts to show differences between estrogen 
receptors in normal human breast tissue and fibrocystic 
tissue have thus far been unsuccessful (Terenius et al, 
1974). 
Randomly tested tumors 
vs Metastatic Tumors 
A 
(59%)PgR+ (41%)PgR 
(33%)ER-
0 (3%)PgR (97%)PgR-
Figure 3. Summary of distribution of ER and PgR in human breast tumors (McGuire, 
1977). 
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Figure 4. Structure of Danazol. 
However, Peters and Lewis (1976) showed that 
dimethyl-1,2-benzanthracene (DMBA) induced mammary cancer 
in rats was sensitive to danazol therapy. They found 
that danazol was effective in inhibiting carcinogenesis 
when given before DMBA and, furthermore, caused regression 
in established tumors. The authors concluded from their 
studies that danazol should be considered for clinical 
trials in the treatment of breast cancer. 
Danazol was synthesized at the Sterling-Winthrop 
Research Institute by Manson and associates (1963), and 
marketed as Danocrine. In reference to danazol, 
Sterling-Winthrop Laboratories makes the following 
statement: "Danazol suppresses the pituitary-ovarian 
axis by inhibiting the output of gonadotropins from the 
pituitary gland. The only other demonstrable hormonal 
effect is weak androgenic activity." (Physicians Desk 
9 
Reference, 1982). Sterling-Winthrop suggests that, for as 
long as danazol is administered, it suppresses luteinizing 
hormone (LH) and follicle stimulating hormone (FSH) 
release. Without stimulation by these gonadotropins, 
ovulation and the full production of estrogen is prevented 
and thus, no corpus luteum or progesterone production 
occurs (Jenkin, 1980). Thus, danazol's therapeutic use 
would be advised for those patients in whom runenorrhea, 
suppression of gonadal steroids or inhibition of pituitary 
gonadotropin was expected to be beneficial. Accordingly, 
the widest clinical application for danazol has been in 
treatment of endometriosis (Dmowski, 1979, Dmowski and 
Cohen, 1978 and Greenblatt et .al, 1971) where it alters 
-- . 
normal and ectopic endometrial tissue, so it becomes 
inactive and atropic (Physicians Desk Reference, 1982). 
In benign breast disease, particularly fibrocystic 
disease, danazol usually produces partial to complete 
disappearance of nodularity. Due to danazol's suppression 
of the hypothalamic-pituitary axis, anovulation and thus 
ammenorrhea result. However, cyclic bleeding usually 
returns within 60-90 days (Physicians Desk Reference, 
1982). 
The androge'nici ty of the drug has been evident in the 
few side effects demonstrated. Weight gain was common, 
with relatively few patients showing mild hirsutism, acne 
or skin oiliness (Greenblatt et al, 1971). 
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In recent studies, danazol has been demonstrated to 
have four major pharmacologic effects: (1) direct 
inhibition of gonadotropin synthesis and/or release 
(Lauersen and Wilson, 1977, Wood et al, 1975, and 
Eldridge, Dmowski and Mahesh, 1974); (2) direct inhibition 
of multiple enzymes of steroidogenesis (Barbieri et al, 
1977, and Barbieri, Camick and Ryan, 1977); (3) inter-
action with androgen, glucocorticoid and progesterone 
receptors in target tissues (Barbieri, Lee and Ryan, 1979, 
and Chamness, Asch and Pauerstein, 1980); and (4) alter~ 
ation of endogenous steroid metabolism (Barbieri, Lee and 
Ryan, 1979, and Barbieri and Ryan, 1981). The majority 
of studies exclude binding to the estrogen receptor as a 
possible method of action (Krey, Robbins and McEwen, 1981, 
Chamness, Asch and Pauerstein, 1980, Barbieri et al, 1979, 
Creange, Potts and Schane, _1979, Woods et al·, 1975, 
Dmowski et al, 1971, and Potts et al, 1974). 
In further examination of danazol's antigonadotropic 
action, Chamness, Asch and Pauerstein (1980) studied its 
ability to bind and translocate androgen, estrogen and 
progesterone receptors both in vivo and in Vitro in the 
rat. Their results showed danazol bound to the proges-
terone and androgen receptors, however, only the androgen 
receptor was translocated to the nucl~us at effective 
antigonadotropic doses. 
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To further understand the mechanism of danazol's 
action in its target cells, the following study was per-
formed to (1) determine the specificity of danazol 
binding to cytosol receptors by competitive binding 
experiments, (2) evaluate the dose response relationship 
of danazol; and (3) to determine the specificity for 
danazol to translocate receptors into the nucleus. 
MATERIALS AND METHODS 
Animal Care 
Nineteen Sprague-Dawley female rats ranging 200-225 
grams in weight, were obtained from Harlan Industries, 
Indianapolis, Indiana. Prior to being sacrificed, they 
were maintained for two weeks in animal quarters on 
Purina Lab Chow (Ralston-Purina Co.) and tap water ad 
libitum. 
Tissue Preparation 
The rats were stunned, decapitated, exsanguated and 
five tissues (uterus, mammary adrenals, hypothalamus and 
pituitary) were removed from each. Immediately upon 
excision, each tissue was placed on a chilled glass 
plate, trimmed of excess fat with a razor blade, weighed 
and quick frozen in dry ice and acetone. Each tissue was 
wrapped individually in foil, labeled and stored in a 
freezer for future competitive binding and dose-response 
experiments. 
For in vitro nuclear translocation experiments, 
uteri from fourteen pre-puberal and thirteen post-puberal 
Sprague-Dawley rats were excised using the same method as 
mentioned above. After being trimmed of excess fat, the 
uteri were incubated in media consisting of 1 ml mimimal 
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essential media with Earle's salts and L-glutamine 
(Grand Island Biological Co.) and l ml of Kreb's Ringer 
Bicarbonate Glucose, pH 7.4 (Urnbreit et al, 1964). Forty 
microliters of indicated steroids in 100% ethanol were 
added to give a final concentration of 2 x 10-B Mand the 
uteri were incubated for two hours at 37°c with gentle 
bubbling of 95% osygen: 5% carbon dioxide in a Dubnoff 
Metabolic Shaking Incubator (GCA Precision Scientific). 
Controls were incubated with 100% ethanol. After incu-
bation, the tissue was blotted, weighed and quick frozen 
in dry ice and acetone for later assay. 
Isolation of Cytoso'l and Nuclear Recep·tors 
All procedures were done on ice and/or in a 
refrigeration unit at 4°c, unless specified otherwise. 
Centrifugations were carried out (depending on the pro-
cedure, sample size and rpm specification) in either a 
Beckman "Airfuge", International Refrigerated Centrifuge, 
Model B-20 (International Equipment Co.) or an Adams 
Sero-fuge. Where microliter volumes were required, 
automatic micro-pipets (Oxford laboratories) were used. 
Isolated cytosol and nuclear receptors were prepared 
by a modification of the methods of Williams and Gorski 
(1974), Chamness ·et al (1979), and Pavlik and Coulson 
(1976). Frozen tissue was cut into small pieces and then 
homogenized in phosphate buffer [P-buffer (5rnM sodium 
14 
phosphate, pH 7.4, lmM thioglycerol, 10% glycerol)] in 
a seven milliliter Ten Broeck pyrex glass-glass tissue 
grinder (about 100-150 mg tissue/ml P-buffer). The 
homogenate was centrifuged (Adams Sero-fuge) eight 
minutes at 1000 x g; the supernatant was taken as the 
cytosol, while the pellet was resuspended in P-buffer 
and recentrifuged twice, then resuspended for one hour 
in buffer with 0.4 M potassium chloride to extract 
receptors from the nuclei. The pellet was then centri-
fuged for 10 minutes at 2000 x g (International 
Refrigerated Centrifuge) and the supernatant was assayed 
for nuclear receptors. 
Receptor Incubations 
Duplicate 200 µl aliquots of cytosol or nuclear 
extract were added to 50 µl of radioactive ligand, while 
another duplicate 200 µl aliquots were added to 50 µl of 
the same ligand with an excess of non-radioactive 
competitors for determination of non-specific binding. 
In addition, to measure total counts, duplicate 200 µl 
aliquots of P-buffer were added to 50 µl of radioactive 
ligand. Final concentrations of radioactive ligands 
-10 (New England Nuclear) were 5 x 10 M [2,4,6,7,16,17-
3 -10 H(N)] estradiol (137.1 Ci/mmole), 5 x 10 M [1,2,4,5, 
6,7,16,17-3H(N)] dihydrotestosterone (179.0 Ci/mmole), 
5 x 10-lO M [1,2,6,7-3H(N)] progesterone (101.0 Ci/mmole), 
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-10 3 5 x 10 M [1,2,6,7- H(N)] corticosterone (105.0 
Ci/mmole). Non-radioactive competitors were 1.67 x 10-7 
M diethylstibesterol, 1.67 x 10-7 M dihydrotestosterone, 
1.67 x 10-7 M progesterone, and 1.67 x 10-7 M 
corticosterone (all are final concentrations). Incu-
bations for cytoplasmic receptors were all three hours 
at o0 c, while those for nuclear receptors were three 
hours at 30°c (estrogen) or 18 hours at o0 c (androgens, 
progestins and corticosteroids). Cytosol and nuclear 
extract were saved (50 µl samples) for protein 
determinations. 
Binding Competition Experiments 
Cytosol was prepared in P-buffer from uteri, mammary, 
adrenal, hypothalamic and pituitary tissue (assayed 
separately). Duplicate aliquots of 200 µl of cytosol 
were incubated with 50 µl of radioactive steroid in 
buffer plus 50 µl of varying concentrations of danazol. 
The danazol (Danocrine) was a gift from Sterling-Winthrop 
Research Institute. Binding was assayed by the hydro-
xylapatite method (HAP) and non-specific binding was 
subtracted. 
Dose Response Experiments 
Cytosol was prepared in P-buffer from uterine 
tissue. Triplicate aliquots of 200 µl of cytosol were 
incubated with 50 µl of varying concentrations of 
radioactive ligand. Competitive binding was checked 
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with 50 µl of non-radioactive ligand added to one aliquot. 
In addition, triplicate aliquots of 50 µl of radioactive 
ligand were incubated with varying microliter concen-
trations of cytosol, with 50 µl of non-radioactive 
competitor in one aliquot to check competitive binding. 
Assay for binding was by the HAP method and non-specific 
binding was subtracted. 
Nuclear Translocation Experiments 
Nuclear extract was prepared in P-buffer from uteri 
of pre- and post-puberal rats. In experiments with the 
pre-puberal uteri, triplicate 200 µl aliquots of the 
nuclear extract ·from control, d_anazol and dihydro-
testosterone (DHT) incubated tissues were added to 50 
µl aliquots of radioactive DHT with a triplicate also 
containing 50 µl of non-radioactive DHT. 
Post-puberal uterine experiment~ were performed, 
using triplicate 200 µl aliquots of the nuclear extract 
from control, danazol, DHT, progesterone, corticosterone 
and estradiol incubated uteri, with a 50 µl aliquot of 
appropriate radioactive ligand. To check for competitive 
binding a triplicate aliquot of 200 µl nuclear extract 
from each incubation with 50 µl of radioactive steroid 
plus 50 µl of non-radioactive competitor was performed. 
Hydroxylapatite Assay 
One milliliter of hydroxylapatite suspension 
[2.5 grams of Bio-Rad HTP, DNA grade, per 100 ml of TP 
buffer (50 mM Tris and 10 mM KH2Po4 )J was added to each 
tube at the end of incubation and kept suspended by 
occasional vortexing (Fisher Scientific Vortex-Genie) 
17 
for 30 minutes. Th.e HAP was then centrifuged 1. 5 minutes 
at 1000 x g, resuspended in 1.5 ml of fresh P-buffer, and 
recentrifuged; this wash was completed twice more. One 
milliliter of 100% ethanol was then added to each pellet 
to extract the radioactive steroid, which was then counted 
in 5 ml of scintillation fluid (19 gm PPO and 1.9 gm 
POPOP/3.8 L toluene}. All counts were made in a Hewlett-
Packard Tri-Carb 300 scintillation counter at Maxey ilats 
Low-Level Nuclear Waste Disposal Site. 
Protein Assay 
Protein concentrations were determined by a modifi-
cation of the Lowry Method (Lowry et al, 1951). To 
precipitate proteins, cold 10% trichloroacetic acid was 
added to 50 µl of cytosol or nuclear extract in a 
cellulose nitrate tube (Beckman, 175 µl capacity) and 
centrifuged in a Beckman Airfuge at 20 psi for 5 minutes. 
The supernatant was aspirated with a disposable transfer 
pipet. To the protein precipitate, 100 µl of 3N sodium 
hydroxide was added, stirred with a toothpick and set 
aside for 10 minutes. Two concentrations (10 µland 
50 µl) of the protein mixture and of a bovine serum 
albumin standard (1 gm/ml) were added to separate test 
tubes and brought to 0.5 ml with distilled water. The 
remaining procedures were identical with those of Lowry 
et al (1951). Measurement of protein concentrations 
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were made in a Bausch and Lomb Spectronic 70, and protein 
was expressed in mg/ml. 
Statistical· Analysis 
Data were analyzed using the Student's t test. 
RESULTS 
To evaluate the validity of the HAP assay and to 
determine conditions to be used in later experiments, 
3 . 
titration curves were run for both H-estradiol and 
cytosol. Specific activity was measured in counts per 
minute/mg of protein. Figure five shows a dose-response 
relationship when the concentration of 3H-estradiol was 
reduced in the incubate, in the presence of 200 µl of 
cytosol. Likewise, by the condition of increasing 
amounts of cytosol, the expected dose relationship was 
seen in specific activity. This indicates as the cytosol 
was increased, the amounts of cytosol receptors were 
increased, therefore the increase in specific binding. 
From these data, experimental protocol for all succeeding 
experiments called for the use of 10-9 M estradiol and 
200 µl cytosol. 
In the first series of experiments performed, the 
competition for steroid receptors with increasing doses 
of danazol were performed in various tissues. The 
results of these experiments are shown in figures six, 
seven, eight and table one, and are expressed as a 
percent of control binding. In all experiments, danazol 
exhibited a dose-response competition with steroid 
receptors. Figure six shows that in mammary tissue, 
competition with the androgen ;receptor exceeded a,11 
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other steroid receptors. Binding was 58% of the control 
at the physiological concentration of 10-9 M danazol 
compared to 88% of the control values of estradiol. 
Danazol was the most efficient competitor of the androgen 
receptor in uterine tissue, with a value of 80% of the 
control at 10-9 M (Figure 7). The competition for 
steroid receptors in pooled adrenal tissue is shown in 
figure eight. This figure shows poor competition with 
-9 
all steroid receptors at 10 M danazol and strong 
competition at the pharmacological dose of 10-S M. 
Due to the lack of cytosol for hypothalamic tissues, 
only two assays were performed. Using only the test 
-9 dose of 10 M, results show in table one that danazol 
competed most effectively with the DHT receptor (73% of 
control) followed by progesterone (86%), corticosterone 
(90%) and estradiol (91%). 
Table 1. Danazol competition for steroid receptors in 
hypothalamic tissue. 
Incubation conditions Estradiol DHT Progesterone Corticosterone 
-9 Danazol (10 M). 91* 73 86, 90 
*Mean percent of cytosol alone which was taken as 100%. 
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Figure 8. Danazol competition for steroid receptors in 
pooled adrenal tissue. 
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A single test was performed with pooled pituitary 
cytosol, showing that danazol at 10-9 M did compete with 
the DHT receptor (65% of control). 
A comparison of steroid binding competition by 
danazol at 10-9 Mis seen in table two. This table 
summerizes the data that danazol competes more favorably 
with the androgen receptor in all tissues with a mean of 
76% of the control followed by estradiol (91%), 
progesterone (92%), and corticosterone (95%). 
In vitro translocation experiments of steroid cytosol 
receptors were performed to better determine receptor 
specificity and biological function. The first experi-
ments were performed on 25 day old, pre-puberal uterine 
tissue and the results are shown in table three. 
Compared to the control specific activity of 426 cpm/mg 
protein, incubation with 10-9 M DHT resulted in a 146% 
increase over the control with 
of 1050 cpm/mg protein (P<.l). 
a mean specific activity 
-6 Danazol at 10 M trans-
located the androgen receptor 85% over the control. 
In all experiments in which in vitro translocation 
was evaluated in adult uterine tissue, danazol did not 
signficantly elevate nuclear receptors in any of the 
steroids tested (Table 4). Danazol translocated the DHT 
receptor most successfully with a value of 68% increase 
over the control. Incubation with respective steroids 
Table 2. 
-9 Comparison of steroid binding competition by danazol at 10 M. 
Competing 
Steroid Receptors 
Estradiol 
DHT 
Progesterone 
Corticosterone 
Uterus Mammary 
92* 87 
80 58 
89 95 
95 98 
*Mean percent of control binding. 
Adrenal Hypothalamus 
92 91 
93 73 
98 86 
96 90 
Mean 
91 
76 
92 
95 
Table 3. In vitro translocation of uterine androgen 
receptor in pre-puberal rats. 
Treatment 
N=6 
Control 
DHT (10-g M) 
Danazol (10- 6 M) 
Specific activity 
cpm/mg protein 
426±146* 
1050±762~ 
790±483 
*Mean± standard deviation 
a P<.1 from controls 
Percent increase 
over control 
146 
85 
27 
Table 4. In vitro translocation of uterine steroid 
receptors in adult rats. 
Treatment 
N=6 
Control 
Estradiol 
Danazol 
Control 
DHT 
Danazol 
Control 
Progesterone 
Danazol 
Control 
Corticosterone 
Danazol 
Specific activity 
cpm/mg protein 
873±200* 
1983±393a 
1041±491 
349±316 
971±354b 
585±692 
570±370 
1229±789 
694±528 
62±74 
95±47 
68±64 
*Mean± standard deviation 
a P<.001 from control 
b P<.05 from control 
Percent increase 
over control 
127 
19 
178 
68 
116 
22 
53 
10 
28 
29 
demonstrated that the cytosol receptor was translocated, 
reflecting values that were significant for DHT (P<.05) 
and highly significant for estradiol (P<.001). 
DISCUSSION 
The mechanism of action of danazol at the sub-
cellular level is not completely understood. However, 
according to current ideas of hormone action, danazol 
should bind to a specific cytosol receptor and trans-
locate it to the nucleus of that particular target cell, 
where it would initiate protein synthesis. It has been 
well substantiated that danazol binds most efficiently 
to the androgen receptor in various target tissues 
(Chamness et al, 1980 and Barbieri et al, 1979). It is 
also suggested that danazol has a somewhat lower affinity 
for the progesterone (Chamness et al, 1980 and Barbieri 
et al, 1979) and glucocorticoid receptor (Barbieri et al, 
1979), with little or no binding to the estrogen 
receptor (Krey ·et al, 1981, Chamness et al, 1980, Woods 
et al, 1975, Creange et al, 1979, Dmowski et al, 1971 and 
Potts et al, 1974). Results. of this study are concurrent 
' . 
with these findings except for demonstrating a low 
affinity binding of danazol to the estrogen receptor. In 
support of these data, Creange· et al,· (1979) has shown 
danazol competition with estrogen receptors of the 
pituitary. 
At physiological doses, danazol competed similarly 
with the estrogen, progesterone and glucocorticoid 
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receptor, showing a somewhat better competition with the 
androgen receptor (.Table 21. In comparison, as 
concentrations of danazol were increased, there was an 
increased competition for all receptors (Figures 6, 
7, and 8) . 
To check for receptor specificity and biological 
function, in vitro translocation experiments were per-
formed on pre- and post-puberal rats.· Tn: ·~ experi-
ments by Chamness ·et ·al (19.801 provides evidence that 
the androgen receptor is the only one effectively trans-
located to the nucleus by danazol. The findings of this 
research, in contrast, show a non-statistical tendency 
of danazol translocating the androgen receptor in 
pre-puberal and adult rats (.Table 3 and 4) along with. a 
somewhat lesser ability to translocate the estrogen, 
progesterone and. glucocorticoid receptor (Table 4) .• 
31 
It is generally agreed that danazol has weak 
androgenic and no estrogenic or anti-estrogenic prop-
erties, while its glucocorticoid and progestational 
effects are still somewhat controversial (Dmowski, 1979, 
Barbieri, et al, 1979, Dmowski et al, 1971 and Potts· et ·a1, 
1974).. Therefore, it must b.e concluded from this study 
that the strong binding and translocation of the androgen 
receptor by danazol is indicative of its androgenic 
responses elicited in vivo. The lower binding affinity 
for the estrogen, progesterone and. glucocorticoid 
receptor and subsequent translocation of these receptors 
may suggest the action of danazol on these receptors is 
not sufficient to stimulate mRNA synthesis and thus 
biological activity. 
Difficulty in obtaining good specific binding 
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counts was a drawback of this procedure, It is sug-
gested that higher counts may be obtained by a wash 
buffer of 1% Tween 80 in phosphate buffer, which has been 
shown to be more successful at diminishing the non-
specific binding (Garola and McGuire, 1978) than 
phosphate buffer alone. 
In summary, evidence presented in this research 
indicates that danazol binds to and translocates estrogen, 
progesterone, glucocorticoid and androgen receptors in 
vitro, though not significantly, while showing the 
greatest success with the androgen receptor in all 
tissues. The dose responsiveness of danazol was 
effectively demonstrated by its increased competition at 
pharmacological concentrations. Furthermore, the 
results indicated that danazol was most effective in 
translocating the androgen receptor in mammary tissue. 
In light of this research, as well as evidence 
reported in the literature, the evaluation of receptor 
bindi11g and nuclear translocation data, will hopefully 
lead to a better understanding of normal steroid target 
cells, cancer modified cells and drug interaction with 
each cell type. 
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